ArticleResearch square2025
Structural Basis for TRF2-RAP1 Recruitment by EBNA1 at the EBV origin of replication.
Paul Lieberman, Samantha Sustek, Troy Messick, Jayaraju Dheekollu, Coltin Albitz, Christopher Chen, Anneliese Faustino, Hsin-Yao Tang, Hee Jong Kim, Kenji Murakami
Abstract readPreprint
In one paragraphArticle in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Samantha SustekThe Wistar Institute.
Troy MessickThe Wistar Institute.
Jayaraju DheekolluThe Wistar Institute.
Coltin AlbitzThe Wistar Institute.
Christopher ChenThe Wistar Institute.
Anneliese FaustinoThe Wistar Institute.
Hee Jong KimUniversity of Pennsylvania.
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9MTargeting the Epigenetic and Metabolic Control of EBV-Epithelial CancersP01CA269043 · NCI · WISTAR INSTITUTE · PI Italo Tempera · 2023 to 2026
$12.0MRegulation of Epstein-Barr Virus LatencyR01CA093606 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2002 to 2022
$6.7MRole of TERRA in Telomere Maintenance and Telomere Stress ResponseR01CA140652 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2010 to 2025
$6.0MFunctional and structural studies of the transition from transcription initiation to elongationR01GM123233 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI MURAKAMI, KENJI · 2017 to 2025
$3.6MDrugging EBNA1 to Treat EBV-Associated Cancers - Diversity SupplementR01CA259171 · NCI · WISTAR INSTITUTE · PI MESSICK, TROY E · 2021 to 2025
$3.3MNCI NIH HHS 75N91019D00024NCI NIH HHS P01 CA269043NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA093606NCI NIH HHS R01 CA140652NCI NIH HHS R01 CA259171NIGMS NIH HHS R01 GM123233
6 · The paper itselfAbstract
Epstein-Barr Nuclear Antigen 1 (EBNA1) is essential for the episomal maintenance and DNA replication of Epstein-Barr virus (EBV) in latently infected cells and acts through binding to
Indexed as
CryoEMEBNA1EBVhRAP1oriPShelterinTERF2TERF2IPTRF2
Identifiers
PMID41282254
PMCPMC12636746
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390